Munich

• Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dos … Ended
  2023-506000-50-00 4 2024-09-26 Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-H
• A phase 2b dose finding study of RMC-035 in participants undergoing open-chest cardiac surgery Ended
  2024-510658-28-00 4 2024-09-24 Loss of renal function following cardiac surgery
• A study to test whether BI 1819479 improves lung function in people with idiopathic pulmonary fibrosis (IPF). Ended
  2023-508395-11-00 4 2024-09-10 idiopathic pulmonary fibrosis
• A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the tr … Ended
  2023-506185-31-00 10 2024-07-18 Idiopathic pulmonary fibrosis (IPF)
• Randomized adaptive assessment of post COVID syndrome treatments (RAPID) Reducing Inflammatory Activity in Patients with post COVID Syndrome … Ended
  2024-511628-16-00 4 2024-07-18 Post Covid Syndrome (PCS)
• A Double-blind, Placebo-controlled, Phase IIb, Multi-center, Twelve-week Prospective Study to Evaluate the Efficacy and Safety of Gemlapodec … Ended
  2023-505086-83-00 4 2024-07-10 Tourette Syndrome
• “A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis” Ended
  2023-503289-22-00 4 2024-07-05 Relapsing Multiple Sclerosis
• Phase 2b study to investigate the safety and efficacy of TIN816 in SA-AKI Ended
  2023-505903-22-00 4 2024-07-02 Sepsis associated acute kidney injury
• An Open-label, Single-dose Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of JNJ-77242113 in Adult Participants Ended
  2023-510161-97-00 3 2024-06-19 Renal Impairment
• A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered i … Ended
  2023-506696-10-00 5 2024-06-18 Non-Small Cell Lung Cancer
• A Proof-of-Concept study to assess the efficacy, safety and tolerability of itepekimab (anti-IL-33 mAb) in participants with non-cystic fibr … Ended
  2023-508663-70-00 4 2024-06-18 Bronchiectasis
• A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined with Atezolizumab in Non-Hodgkin's … Ended
  2023-506820-10-00 9 2024-06-11 B-Cell Malignancies
• A Two-Part Study to Assess the Effectiveness, Safety, and Blood Levels of Repeat Doses of Inhaled ETD001 in People with Cystic Fibrosis Ended
  2023-504092-25-00 4 2024-06-04 Cystic Fibrosis
• AMX0035 and Progressive Supranuclear Palsy Ended
  2023-505893-14-00 5 2024-06-04 Progressive Supranuclear Palsy
• A randomized, open label, multicenter phase II/III trial of sacituzumab govitecan compared to standard of care in metastatic, refractory col … Ended
  2023-509771-17-00 10 2024-06-04 Metastatic Colorectal cancer (mCRC)
• [68Ga]Ga-PentixaFor-PET imaging for staging of marginal zone lymphoma Ended
  2022-500918-25-00 5 2024-05-20 Marginal Zone Lymphoma
• A Single-blind, Phase 2, Multi-center, Randomized Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of the Relaxin Agonist … Ended
  2023-503504-88-00 4 2024-05-13 Hepatorenal Syndrome – Acute Kidney Injury
• A Study of Nicotine Freshmint Mouthspray in E-cigarette Users Willing to Quit Ended
  2023-505036-35-00 5 2024-04-23 Vaping cessation in e-cigarette users
• Open-label single-arm, multicenter clinical trial to evaluate patient acceptability of a new CREON formulation of Pancreas Powder gastro-res … Ended
  2023-503256-27-00 3 2024-04-18 patients with cystic fibrosis suffering from pancreatic exocrine insuf
• A phase Ib/II single-arm, multicenter study of sacituzumab-govitecan, a TROP-2 targeting antibody linked with SN38, for patients with metast … Ended
  2023-505257-40-00 9 2024-04-17 metastatic esophagogastric adenocarcinoma (Stage IV)
• Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis Ended
  2023-510127-30-00 1 2024-04-17 Relapsing Remitting Multiple Sclerosis (RRMS)
• A 52-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3) Ended
  2023-503693-20-01 5 2024-04-10 Severe eosinophilic asthma
• A Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Choroidal Neovascularization Secondary to Pathologic Myopia Ended
  2023-506707-25-00 5 2024-04-09 Choroidal neovascularization secondary to pathologic myopia
• Study in Participants With Normal Kidney Function and Reduced Kidney Function to Test How Kidney Function Can Change What Happens to Obeldes … Ended
  2023-504780-17-00 3 2024-03-19 Renal Impairment

Showing 865–888 of 1,080 trials